Aspects of the pathogenesis of the Rauscher murine leukemia virus infection

Among the oncogenic viruses, Rauscher murine leukemia virus (R-MuLV) (RAUSCHER 1962) occupies a relatively prominent place in experimental neoplasia. Therefore, we performed a series of experiments to acquire more information about the morphological changes occurring during R-MuL V-induced infection, which is also called Rauscher disease of mice (FINK et a!. 1964). During these studies, we were able to determine the morphological expression of the cytopathic effects of R-MuLV and the neoplastic nature of Rauscher disease. Afterwards, the cytopathic effect of R-MuLV on adult and embryonic tissue was studied both light- and electron-microscopically. Finally, we made an attempt to develop a convenient method for the transplantation of hemopoietic cells infected with R-MuL V. This investigation led to the identification of mesenteric hemopoietic colonies. The occurrence of mesenteric hemopoietic colonies was studied in several strains of mice, and to complete the investigation also in Macaca fascicularis monkeys

Microscopic Studies Of The Foetal Lung Development In The OneHumped Camel (Camelus dromedarius) Obtained From Kano Abattoir

Eighty – seven foetal lung samples from camels (Camelus dromedarius) were collected at Kano abattoir to study lung development. Four phases of the lung development were observed as follows; pseudo-glandular phase was between 10.5 cm to 38.2 cm crown-rump length, with endodermal buds and prominent mesenchymal cells. Canalicular phase was observed between 38.7 cm to 62.2 cm  crownrump length and was characterized by thinning of the endodermal buds and invasion of capillaries. Saccular phase was noticed at 65.6 cm to 82.6 cm crown-rump length when thick intercellular septa were noticed. Alveolar phase was noticed between 85.9 cm to 121 cm crown-rump length when primitive alveolar was noticed. This study has established phases of lung development in the camel and serves as baseline information for scientific knowledge. Keywords: Foetal lung, camel (Camelus dromedarius), crown-rump length, lung development and Kano abattoir

Phytochemical, antifungal and acute toxicity studies of Mitracarpus scaber Zucc. whole plant extracts

Mitracarpus scaber have been reported in the treatment of various ailments such as ulcer, cancer, skin diseases etc. It is therefore important to investigate these plant parts to ascertain their therapeutic potentials. The Mitracarpus scaber whole plant was extracted with water and methanol, screened for their phytochemical properties and antifungal effects. The plant samples were also investigated for alkaloid, flavonoids, saponins, tannins and phenolic contents using quantitative techniques. The antifungal activities of the plant samples were tested against Candida albicans, Trichophyton mentagrophytes, Microsporum auduounii and Aspergillus flavus. The Minimum Inhibitory Concentration (MIC) and Minimum Fungicidal Concentration (MFC) of the extracts were also determined. Flavonoid, steroid, triterpenes, tannins, carbohydrate, glycoside, phenols were detected in both extracts while anthraquinones was absent. Alkaloid was detected in the aqueous extract but absent in methanol extract. Quantitatively, the phenols (97.0 mg/g) was the highest phytochemical detected in the plant while the lowest was alkaloid (9.2 mg/g). Toxicity of the samples was expressed as LD50, it was found above 5000 mg/kg and did not cause mortality in all the tested rats. Aqueous extract only showed inhibition on Candida albicans and Trichophyton mentagrophytes with no inhibition on Microsporum auduounii and Aspergillus flavus while ethanol extract only showed inhibition on Candida albicans with no inhibition on Microsporum auduounii, Trichophyton mentagrophytes and Aspergillus flavus at the lowest concentration 12.5 mg/ml. The aqueous extract has MIC and MFC of 12.5 mg/ml and 25 mg/ml respectively against Candidaalbicans and Trichophyton mentagrophytes. Thus, the traditional claims of the uses of the plants as antifungal agents were therefore supported

Pengaruh Faktor Keperilakuan Organisasi Terhadap Kegunaan Sistem Akuntansi Keuangan Daerah Di Kabupaten Klaten

This study, entitled "Effects of Organizational Behavioral Factors to Regional Financial Accounting System utilities in Klaten District". This study aims to determine, analyze and obtain empirical evidence about the influence of behavioral factors of the organization's financial accounting system usability area in the district of Klaten in accordance Permendagri 64 2014 Top 59 Amendment Regulation 2007. This study was conducted using a survey method with questionnaires. The study population was all the heads of the finance department at the office of Sub SKPD Klaten district. Data analysis was performed to test the validity and reliability, test classic assumptions and hypothesis testing with multiple linear regression method. This study uses primary data and obtained by distributing questionnaires to 60 respondents. The results showed that the behavioral variables organization (supervisor support, clarity of purpose, training) affects the area of financial accounting system usability. This shows that support for the boss, clarity of purpose and training can affect usability in realizing the area of financial accounting system is better in an agency

Ultra violet sensors based on nanostructured ZnO spheres in network of nanowires: a novel approach

The ZnO nanostructures consisting of micro spheres in a network of nano wires were synthesized by direct vapor phase method. X-ray Photoelectron Spectroscopy measurements were carried out to understand the chemical nature of the sample. ZnO nanostructures exhibited band edge luminescence at 383 nm. The nanostructure based ZnO thin films were used to fabricate UV sensors. The photoresponse measurements were carried out and the responsivity was measured to be 50 mA W−1. The rise and decay time measurements were also measured

Tracking development assistance for health and for COVID-19 : a review of development assistance, government, out-of-pocket, and other private spending on health for 204 countries and territories, 1990-2050

Background The rapid spread of COVID-19 renewed the focus on how health systems across the globe are financed, especially during public health emergencies. Development assistance is an important source of health financing in many low-income countries, yet little is known about how much of this funding was disbursed for COVID-19. We aimed to put development assistance for health for COVID-19 in the context of broader trends in global health financing, and to estimate total health spending from 1995 to 2050 and development assistance for COVID-19 in 2020. Methods We estimated domestic health spending and development assistance for health to generate total health-sector spending estimates for 204 countries and territories. We leveraged data from the WHO Global Health Expenditure Database to produce estimates of domestic health spending. To generate estimates for development assistance for health, we relied on project-level disbursement data from the major international development agencies' online databases and annual financial statements and reports for information on income sources. To adjust our estimates for 2020 to include disbursements related to COVID-19, we extracted project data on commitments and disbursements from a broader set of databases (because not all of the data sources used to estimate the historical series extend to 2020), including the UN Office of Humanitarian Assistance Financial Tracking Service and the International Aid Transparency Initiative. We reported all the historic and future spending estimates in inflation-adjusted 2020 US$, 2020 US$ per capita, purchasing-power parity-adjusted US$per capita, and as a proportion of gross domestic product. We used various models to generate future health spending to 2050. Findings In 2019, health spending globally reached$8. 8 trillion (95% uncertainty interval [UI] 8.7-8.8) or $1132 (1119-1143) per person. Spending on health varied within and across income groups and geographical regions. Of this total,$40.4 billion (0.5%, 95% UI 0.5-0.5) was development assistance for health provided to low-income and middle-income countries, which made up 24.6% (UI 24.0-25.1) of total spending in low-income countries. We estimate that $54.8 billion in development assistance for health was disbursed in 2020. Of this,$13.7 billion was targeted toward the COVID-19 health response. $12.3 billion was newly committed and$1.4 billion was repurposed from existing health projects. $3.1 billion (22.4$2.4 billion (17.9%) was for supply chain and logistics. Only $714.4 million (7.7$1519 (1448-1591) per person in 2050, although spending across countries is expected to remain varied. Interpretation Global health spending is expected to continue to grow, but remain unequally distributed between countries. We estimate that development organisations substantially increased the amount of development assistance for health provided in 2020. Continued efforts are needed to raise sufficient resources to mitigate the pandemic for the most vulnerable, and to help curtail the pandemic for all. Copyright (C) 2021 The Author(s). Published by Elsevier Ltd.Peer reviewe

Track D Social Science, Human Rights and Political Science

Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/138414/1/jia218442.pd

Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021

Background: Detailed, comprehensive, and timely reporting on population health by underlying causes of disability and premature death is crucial to understanding and responding to complex patterns of disease and injury burden over time and across age groups, sexes, and locations. The availability of disease burden estimates can promote evidence-based interventions that enable public health researchers, policy makers, and other professionals to implement strategies that can mitigate diseases. It can also facilitate more rigorous monitoring of progress towards national and international health targets, such as the Sustainable Development Goals. For three decades, the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) has filled that need. A global network of collaborators contributed to the production of GBD 2021 by providing, reviewing, and analysing all available data. GBD estimates are updated routinely with additional data and refined analytical methods. GBD 2021 presents, for the first time, estimates of health loss due to the COVID-19 pandemic. Methods: The GBD 2021 disease and injury burden analysis estimated years lived with disability (YLDs), years of life lost (YLLs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries using 100 983 data sources. Data were extracted from vital registration systems, verbal autopsies, censuses, household surveys, disease-specific registries, health service contact data, and other sources. YLDs were calculated by multiplying cause-age-sex-location-year-specific prevalence of sequelae by their respective disability weights, for each disease and injury. YLLs were calculated by multiplying cause-age-sex-location-year-specific deaths by the standard life expectancy at the age that death occurred. DALYs were calculated by summing YLDs and YLLs. HALE estimates were produced using YLDs per capita and age-specific mortality rates by location, age, sex, year, and cause. 95% uncertainty intervals (UIs) were generated for all final estimates as the 2·5th and 97·5th percentiles values of 500 draws. Uncertainty was propagated at each step of the estimation process. Counts and age-standardised rates were calculated globally, for seven super-regions, 21 regions, 204 countries and territories (including 21 countries with subnational locations), and 811 subnational locations, from 1990 to 2021. Here we report data for 2010 to 2021 to highlight trends in disease burden over the past decade and through the first 2 years of the COVID-19 pandemic. Findings: Global DALYs increased from 2·63 billion (95% UI 2·44–2·85) in 2010 to 2·88 billion (2·64–3·15) in 2021 for all causes combined. Much of this increase in the number of DALYs was due to population growth and ageing, as indicated by a decrease in global age-standardised all-cause DALY rates of 14·2% (95% UI 10·7–17·3) between 2010 and 2019. Notably, however, this decrease in rates reversed during the first 2 years of the COVID-19 pandemic, with increases in global age-standardised all-cause DALY rates since 2019 of 4·1% (1·8–6·3) in 2020 and 7·2% (4·7–10·0) in 2021. In 2021, COVID-19 was the leading cause of DALYs globally (212·0 million [198·0–234·5] DALYs), followed by ischaemic heart disease (188·3 million [176·7–198·3]), neonatal disorders (186·3 million [162·3–214·9]), and stroke (160·4 million [148·0–171·7]). However, notable health gains were seen among other leading communicable, maternal, neonatal, and nutritional (CMNN) diseases. Globally between 2010 and 2021, the age-standardised DALY rates for HIV/AIDS decreased by 47·8% (43·3–51·7) and for diarrhoeal diseases decreased by 47·0% (39·9–52·9). Non-communicable diseases contributed 1·73 billion (95% UI 1·54–1·94) DALYs in 2021, with a decrease in age-standardised DALY rates since 2010 of 6·4% (95% UI 3·5–9·5). Between 2010 and 2021, among the 25 leading Level 3 causes, age-standardised DALY rates increased most substantially for anxiety disorders (16·7% [14·0–19·8]), depressive disorders (16·4% [11·9–21·3]), and diabetes (14·0% [10·0–17·4]). Age-standardised DALY rates due to injuries decreased globally by 24·0% (20·7–27·2) between 2010 and 2021, although improvements were not uniform across locations, ages, and sexes. Globally, HALE at birth improved slightly, from 61·3 years (58·6–63·6) in 2010 to 62·2 years (59·4–64·7) in 2021. However, despite this overall increase, HALE decreased by 2·2% (1·6–2·9) between 2019 and 2021. Interpretation: Putting the COVID-19 pandemic in the context of a mutually exclusive and collectively exhaustive list of causes of health loss is crucial to understanding its impact and ensuring that health funding and policy address needs at both local and global levels through cost-effective and evidence-based interventions. A global epidemiological transition remains underway. Our findings suggest that prioritising non-communicable disease prevention and treatment policies, as well as strengthening health systems, continues to be crucially important. The progress on reducing the burden of CMNN diseases must not stall; although global trends are improving, the burden of CMNN diseases remains unacceptably high. Evidence-based interventions will help save the lives of young children and mothers and improve the overall health and economic conditions of societies across the world. Governments and multilateral organisations should prioritise pandemic preparedness planning alongside efforts to reduce the burden of diseases and injuries that will strain resources in the coming decades. Funding: Bill & Melinda Gates Foundation